Latest News

Findings point toward one of first therapies for Lou Gehrig's disease

Researchers have determined that a copper compound known for decades may form the basis for a therapy for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. In humans, prior to this, no therapy for ALS has ever been discovered that could extend lifespan more than a few additional months.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Scientists discover link between common medications and serious falls in older men

  • Sleepy fruitflies get mellow

  • Research grasps how brain plans gripping motion

  • How to digitally stoke that old-time auction fever

  • Autism costs estimated to reach nearly 0 billion, potentially trillion, by 2025

  • Coffee consumption habits impact the risk of mild cognitive impairment

  • Very early birth linked to introversion, neuroticism, risk aversion in adulthood

  • Where memory is encoded and retrieved: New findings in a long-standing debate

  • Neurology researchers evaluate evidence base for tests for clinical cognitive assessment

  • Majority rule: Why conformity can actually be a good thing

  •